Helix BioPharma Announces Filing of Interim Financial Statements

Toronto, Ontario — December 15, 2025 — Leads & Copy — Helix BioPharma Corp. (TSX:HBP) has filed its unaudited interim financial statements for the period ended October 31, 2025, along with management’s discussion and analysis, and certifications of the CEO and CFO. The Interim Filings are accessible on SEDAR+ and on the company's website.

Helix BioPharma is an oncology company focused on solutions for hard-to-treat cancers. Its pipeline is led by Tumor Defense Breaker™ L-DOS47, currently in Phase Ib studies for non-small cell lung cancer.

The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, an oral gemcitabine prodrug.

Jacek Antas, Director
+1 857 208 7687
corporate@helixbiopharma.com

Source: Helix BioPharma